Dentons has advised Farmak on a series of acquisitions from a portfolio company of private equity house Novator.
According to Dentons, “Farmak acquired pharmaceutical marketing companies in the Czech Republic and Slovakia, together with the relevant IP rights and trademarks, and in a separate transaction, a Ukrainian business owning a product portfolio, selected assets, and IP rights and trademarks.”
Farmak is a Ukrainian pharmaceutical company with a 6% market share. According to Dentons, “through this transaction, Farmak will increase its presence in the European Union while strengthening its position in the cardiology and cough and cold segments.”
The Dentons team included Prague-based Partner Petr Zakoucky, Counsel Lukas Vymola, and Associates Petr Mueller, Adam Prerovsky, Stepanka Havlikova, Blanka Crhakova, Jan Tyls, Tomas Jonas, and Michael Mracek, Bratislava-based Partner Juraj Gyarfas and Associates Jan Dulovic, Alen Gondek, Gabriel Kulik, Michal Distler, and Tatiana Jevcakova, Kyiv-based Partners Adam Mycyk and Maksym Sysoiev, Counsels Anna Tkachenko, Oksana Horban, and Evgenia Prudko, and Associates Volodymyr Omelchenko, Victor Marchan, and Roman Mehedynyuk, and Budapest-based Partner Rob Irving.
Editor's Note: After this article was published, CEE Legal Matters learned that Asters advised Farmak as well. The firm's team included Partners Vadym Samoilenko and Julia Semeniy, Counsel Oles Kvyat, and Senior Associates Bohdana Marchuk and Olena Kozhokar.
Subsequently, we learned that Prague's Siroky Zrzavecky advised Novator and Xantis Pharma on the deal. The firm's team included Partner Jan Zrzavecky and Attorney at Law Pavel Vejmola.
